Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Spooks With Phase III Aducanumab Changes

Executive Summary

Recruiting more patients into a trial to retain statistical power is standard practice, but with other companies discontinuing late-stage investigational Alzheimer's therapies, the difficulty in maintaining confidence in the development of new therapies for the condition has been underlined by investor responses to Biogen's alterations.


Related Content

Clinical Trials In Review: Big Hits And Misses In 2018
Eisai Adds To Alzheimer's Arsenal With Anti-Tau Drug
United Neuroscience Hopes To Revive Vaccine Approach To Alzheimer’s
Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology
Biogen Moves Into Neuropsychiatry With Pfizer AMPA Receptor Modulator
Stock Scan February 2018: Wet But Above Water
Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance
M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts